Entera Bio Reaches FDA Alignment on EB613 Phase 3 Study to Support NDA
Entera Bio Ltd. announced positive FDA feedback for a Phase 3 osteoporosis study and a $275 million private placement, fortifying the company's financial ability to advance core assets.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day